Brand Name: Verm-1 Tablet
Active Ingredient: Mebendazole
When is Verm-1Tablet prescribed for?
- Cystic echinococcosis caused by Echinococcus granulosus (dog tapeworm).
- Alveolar echinococcosis, caused by Echinococcus multilocularis (fox tapeworm).
- Drug treatment of hydatid disease with Verm1 500 mg can lead to stabilization of Echinococcus granulosus, cysts (cystic echinococcosis) and can lead to alveolar hydatid disease (E. multilocularis) the progression of the disease to affect favorably, but without killing the parasites reliable.
- Verm1 500 mg therefore indicated for perioperative prophylaxis in conjunction with metastases surgery (especially with E. granulosus), in surgically reconstructed cases incomplete and in unresectable disease (particularly with E. multilocularis).
How should you take Verm-1 Tablet?
Adults and children 14 years Echinococcosis Directional dose for initiation of therapy:
• First Week: 3 × 1 tablet daily.
• Second Week: 3 x 2 tablets daily.
• From 3 Week: 3 × 3 tablets daily.
• The maintenance dose should, on the basis of plasma level determinations, are carefully defined individually (target plasma level: 250 nmol, measured 4 hours after taking the morning dose).
• Daily doses of more than 12 tablets (6 g mebendazole) are rarely necessary according to experience.
• For better absorption, it is advisable to take Verm1 500 mg together with high fat foods.
• At the beginning of treatment and at multi-week intervals during long-term therapy, the blood parameters and liver function should be monitored.
• The perioperative prophylaxis usually starts shortly before surgery and continued during up to 3 months afterwards.
When you should not take Verm-1 Tablet?
- Patients with known hypersensitivity to mebendazole.
- Children under 1 year.
Special Drug interaction with Verm-1 Tablet
Cimetidine may inhibit the metabolism of Mebendazole in liver, resulting in increased plasma concentrations of the drug.
Special warnings and precautions about Verm-1 Tablet
- In the absence of children under 1 year experience and have been described in rare cases, reports of convulsions, Verm1 should not be used in this age group.
- In the long-term treatment of hydatid disease which aids monitoring of treatment by a specialist is recommended.
- In rare cases, reversible liver function disturbances, hepatitis, and neutropenia in patients have been reported, which were treated with mebendazole in the standard dosage. These events were observed together with glomerulonephritis, even at much higher doses than recommended and for treatment over an extended period of time. During the treatment, the liver and kidney parameters are monitored regularly.
- In patients with hepatic or Gallenwegstörungen (hepatocellular insufficiency, cholestasis) must initial and maintenance dosage should be reduced. During long-term treatment is necessary in these patients, a particularly close monitoring of plasma mebendazole levels and liver function.
- For use of Verm1 500 mg in children under 14 years, very little experience.
- Diabetics can reduce Verm1 500 mg insulin requirement, so the blood sugar levels should be closely monitored in these patients.
- Results of a Case-Control Study, which the onset of Stevens-Johnson syndrome / toxic epidermal necrolysis (SJS / TEN) examined, suggest that a possible association between SJS / TEN and the simultaneous administration of mebendazole and metronidazole is. There are no other data that indicate such a drug interaction. Therefore, concomitant administration of mebendazole and metronidazole should be avoided.
Special information if you are pregnant or breastfeeding
- Clinical experience in pregnant women is limited.
- Mebendazole is contraindicated during pregnancy, especially during the first trimester cannot be administered unless clearly necessary.
- It is not known whether mebendazole is excreted into breast milk.
- In the application of Verm1 500 mg during lactation is recommended to stop breastfeeding.
Possible Side effects with Verm-1 Tablet